Clinical Trial Update: Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of cabozantinib and erlotinib for metastatic pancreatic adenocarcinoma with EGFR and c-Met co-expression was terminated; results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Patrick Joseph Loehrer Sr. | Conditions: Pancreatic Adenocarcinoma Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2020-08-27